Sten R Sörensen, CEO CerenoScientific

Cereno’s CEO on being granted “Compassionate Use”

Cereno Scientific has been granted Expanded Access, also known as "compassionate use," by the FDA for drug candidate CS1 in rare disease pulmonary arterial...
ThomasFeldthus_CEO_Saniona

Saniona raises capital to advance epilepsy programme

Saniona’s CEO Thomas Feldthus visited BioStock's studio for an interview discussing the company's drug development pipeline with epilepsy candidate SAN711 leading the way. We...
SørenBregenholt, CEO AlligatorBioscience

Alligator meets primary endpoint with CD40 agonist in pancreatic cancer

Alligator Bioscience has released positive top-line data from the phase II trial assessing the efficacy of the CD40 agonist mitazalimab in pancreatic cancer. Having...
Saniona

BioStock Investor Pitch: Saniona

Danish biopharma company Saniona has a broad drug development pipeline based on ion channel modulators. The company's focus is on epilepsy, and candidate SAN711...
Oncoinvent

BioStock Investor Pitch: Oncoinvent

Oncoinvent's CEO Anders Månsson visited BioStock's studio to talk about the development of the radiopharmaceutical Radspherin for peritoneal carcinomatosis. In his presentation, he delves...
Christian Kanstrup, CEO Evaxion

Can AI help solve cancer? – Evaxion Biotech talks AI, cancer...

At the end of August, Evaxion Biotech announced a change in top management, hiring Christian Kanstrup as CEO. Kanstrup stopped by the BioStock Studio...
NordicLifeScience Days 2023

NLSDays 2023: Positive vibes across Nordic life science partnering landscape

BioStock attended NLSDays 2023, the 10th anniversary edition of the Nordic Life Science partnering conference. On November 29 and 30, we got a chance...
Carlos de Sousa, CEO Ultimovacs

Ultimovacs CEO: “Data could put us at the forefront of cancer...

Ultimovacs has announced positive survival data from the phase II NIPU trial assessing the universal cancer vaccine UV1 in malignant mesothelioma. The company’s CEO...
CLS vd Dan Mogren i korridoren på Medicon Village, Lund

CLS looks forward to further expansion

Medtech company Clinical Laserthermia Systems has now joined the group of reporting companies. CEO Dan Mogren visited BioStock's studio to summarise the most important...
Sarah Fredriksson, vd, Aqilion

Aqilion on phase I results and potential IPO

Aqilion recently announced positive results from the phase I study with their candidate AQ280. The candidate targets eosinophilic esophagitis and is tested in Aqilion's...